Futura Medical signs marketing and distribution deal with Church & Dwight

Futura Medical, a pharmaceutical group that develops innovative products for consumer healthcare, has signed an agreement with Church & Dwight Co., for the marketing and distribution of CSD500, Futura's new condom product under the Trojan brand.

Futura Medical, a pharmaceutical group that develops innovative products for consumer healthcare, has signed an agreement with Church & Dwight Co., for the marketing and distribution of CSD500, Futura's new condom product under the Trojan brand.

Under the terms of the agreement, Church & Dwight will hold the rights to manufacture, market and distribute CSD500 in North America and in a number of key European territories.

The company said that details of the deal will not be disclosed, but did reveal that it will receive an upfront payment and royalties on all product sales, along with certain minimum performance guarantees.

James Barder, Futura's Chief Executive, said: "We are delighted to sign this pivotal agreement with Church & Dwight for the marketing of CSD500 as a Trojan-branded condom in North America and in key territories in Europe. Trojan is one of the world's biggest condom brands and the number one brand in North America.

"The agreement is in line with the board's preferred strategy of licensing CSD500 on a geographic basis to condom distributors that hold leading positions in their regions. We continue to negotiate CSD500 rights for other major territories and believe that this strategy will create optimal value for shareholders."

Futura's share price climbed 9.82% to 61.50p by 13:32.

NR

Recommended

Imperial Brands has an 8.3% yield – but what’s the catch?
Share tips

Imperial Brands has an 8.3% yield – but what’s the catch?

Tobacco company Imperial Brands boasts an impressive dividend yield, and the shares look cheap. But investors should beware, says Rupert Hargreaves. H…
20 May 2022
Investing in drugmakers: uncommon profits from curing rare diseases
Share tips

Investing in drugmakers: uncommon profits from curing rare diseases

Treatments for medical conditions with only a small number of sufferers can still be very attractive for pharmaceutical companies and investors becaus…
20 May 2022
Share tips of the week – 20 May
Share tips

Share tips of the week – 20 May

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
20 May 2022
Delivering profits: should you buy Royal Mail shares?
Share tips

Delivering profits: should you buy Royal Mail shares?

The volume of parcels delivered by Royal Mail soared during the pandemic, and so did its profits. But it has been coming under pressure lately. So, as…
19 May 2022

Most Popular

The ten highest dividend yields in the FTSE 100
Income investing

The ten highest dividend yields in the FTSE 100

Rupert Hargreaves looks at the FTSE 100’s top yielding stocks for income investors to consider.
18 May 2022
Imperial Brands has an 8.3% yield – but what’s the catch?
Share tips

Imperial Brands has an 8.3% yield – but what’s the catch?

Tobacco company Imperial Brands boasts an impressive dividend yield, and the shares look cheap. But investors should beware, says Rupert Hargreaves. H…
20 May 2022
Barry Norris: we’re already in the 1970s. Here’s how to invest
Investment strategy

Barry Norris: we’re already in the 1970s. Here’s how to invest

Merryn talks to Barry Norris of Argonaut capital about the parallels between now and the 1970s; the transition to “green” energy; and the one sector w…
19 May 2022